{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:58:03Z","timestamp":1788202683259,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The clinical deterioration commonly experienced by pediatric patients with pulmonary arterial hypertension (PAH) has motivated a shift in the treatment of pulmonary hypertension (PH) through innovations in surgical salvage interventions. The Occlutech fenestrated atrial septal defect (FASD) Occluder and the atrial flow regulator (AFR), which provides a protective, atrial-level shunt during hypertensive crises, have found an important role in treating pediatric patients with PAH. Other groups of pediatric patients with PH may also benefit from a similar protective physiology. The primary aim of this work is to present a single center's experience with AFR and FASD devices for managing a heterogeneous group of pediatric PH patients. A secondary goal is to identify hemodynamic changes and complications following device implantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We performed a retrospective review of all pediatric PH patients who, after being found suitable, either successfully or unsuccessfully received an FASD or AFR device between January 2015 and December 2021 at the Stollery Children's Hospital in Edmonton, Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen patients (eight female) with a median age of 4.6 (range 0.3\u201317.9) years and a median body mass index of 15.1 (Q<jats:sub>1<\/jats:sub>\u2009=\u200913.8, Q<jats:sub>3<\/jats:sub>\u2009=\u200916.8) kg\/m<jats:sup>2<\/jats:sup> underwent device implantation: five received FASDs, eight received AFRs, and one was ultimately unable to receive an implant due to thrombosed iliac vessels and required surgical intervention. Of the fourteen patients, seven were in group 1 (PAH), one was in group 3 (lung disease), and six were in group 5 (primarily pulmonary hypertension vascular disease) under the World Symposium PH classification. All patients were on mono-, dual-, or triple-drug PH therapy. Device stabilization was not possible for two patients, who then required a repeat catheterization. Of the group 1 patients, three AFR and three FASD implants were successful, while one FASD implant was unsuccessful due to thrombosed vessels. At a six-month clinical assessment, all group 1 patients had patent devices and improved WHO FCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This work presents a single center's experience with AFR and FASD implants in a heterogeneous group of fourteen pediatric patients with severe PH. This treatment strategy is novel in the pediatric population and so this work provides momentum for future studies of interventional cardiac catheterization procedures for pediatric patients with PH. Further collaborations are required to develop criteria to identify ideal pediatric candidates and optimally time interventions in order to maximize the benefits of this treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1073336","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T11:01:43Z","timestamp":1674644503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients"],"prefix":"10.3389","volume":"11","author":[{"given":"David Edward","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Averin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Pietrosanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/hrt.2005.077669","article-title":"Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension","volume":"92","author":"Micheletti","year":"2006","journal-title":"Heart"},{"key":"B2","doi-asserted-by":"publisher","first-page":"ii42","DOI":"10.1136\/heartjnl-2015-308378","article-title":"Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK","volume":"102","author":"Kozlik-Feldmann","year":"2016","journal-title":"Heart"},{"key":"B3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1017\/S1047951112001771","article-title":"Atrial septal defect closure with an Amplatzer septal occluder fenestrated with a coronary stent in a child with pulmonary arterial hypertension","volume":"23","author":"Skinner","year":"2013","journal-title":"Cardiol Young"},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.acvd.2014.09.005","article-title":"Transcatheter closure of atrial septal defect with the Figulla\u00ae ASD Occluder: A comparative study with the Amplatzer\u00ae Septal Occluder","volume":"108","author":"Godart","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"bcr2014205493","DOI":"10.1136\/bcr-2014-205493","article-title":"Case report: ASD closure under pressure","author":"Shebani","year":"2014","journal-title":"BMJ Case Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00246-016-1530-4","article-title":"Atrial septal defect closure with Occlutech\u00ae ASD fenestrated device in a child with severe pulmonary hypertension","volume":"38","author":"Gonzalez-Barlatay","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/icvts\/ivy165","article-title":"Atrial flow regulator for failing Fontan circulation: an initial European experience","volume":"27","author":"Manuri","year":"2018","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1017\/S1047951118000720","article-title":"Creation of a defined and stable Fontan fenestration with the new Occlutech Atrial Flow Regulator (AFR\u00ae)","volume":"28","author":"Lehner","year":"2018","journal-title":"Cardiol Young"},{"key":"B9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ccd.22556","article-title":"Shunt reduction with a fenestrated Amplatzer device","volume":"76","author":"Kretschmar","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"B10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0002-9149(96)00723-0","article-title":"Transcatheter fenestration dilation and\/or creation in postoperative Fontan patients","volume":"79","author":"Kreutzer","year":"1997","journal-title":"Am J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ccd.26081","article-title":"Extracardiac Fontan fenestration using the SafeSept transseptal guidewire and snare-controlled diabolo-shaped covered-stent placement","volume":"87","author":"Casadonte","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ccd.26042","article-title":"Creation of a transcatheter fenestration in children with failure of Fontan circulation: focus on extracardiac conduit connection","volume":"86","author":"Rupp","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.21037\/cdt-22-244","article-title":"Hemodynamic indices in pulmonary hypertension: a narrative review","volume":"12","author":"Manek","year":"2022","journal-title":"Cardiovasc Diagn Ther"},{"key":"B14","unstructured":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.21037\/cdt.2018.01.08","article-title":"Pulmonary vascular pathophysiology","volume":"8","author":"Chamarthy","year":"2018","journal-title":"Cardiovasc Diagn Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.32604\/CHD.2022.018590","article-title":"Multi-institutional US experience of the occlutech AFR device in congenital and acquired heart disease","volume":"17","author":"O\u2019Callaghan","year":"2022","journal-title":"Congenit Heart Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21693\/1933-088X-18.1.4","article-title":"Atrial septal defect-associated pulmonary hypertension: outcomes of closure with a fenestrated device","volume":"18","author":"Kaley","year":"2019","journal-title":"Adv Pulm Hypertens"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ccd.27233","article-title":"Atrial septostomy with a predefined diameter using a novel Occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension","volume":"90","author":"Rajeshkumar","year":"2017","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1073336\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T11:01:44Z","timestamp":1674644504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1073336\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":19,"alternative-id":["10.3389\/fped.2023.1073336"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1073336","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"article-number":"1073336"}}